495 related articles for article (PubMed ID: 28830795)
1. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
3. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
4. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.
Xin F; Yu Y; Yang ZJ; Hou LK; Mao JF; Xia L; Wang X; Cao XC
Tumour Biol; 2016 Jun; 37(6):8445-54. PubMed ID: 26733172
[TBL] [Abstract][Full Text] [Related]
5. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.
Wright JL; Takita C; Reis IM; Zhao W; Saigal K; Wolfson A; Markoe A; Moller M; Hurley J
Cancer; 2013 Jan; 119(1):16-25. PubMed ID: 22736498
[TBL] [Abstract][Full Text] [Related]
6. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
[TBL] [Abstract][Full Text] [Related]
7. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
8. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
[No Abstract] [Full Text] [Related]
9. The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy.
Lanning RM; Morrow M; Riaz N; McArthur HL; Dang C; Moo TA; El-Tamer M; Krause K; Siu C; Hsu M; Zhang Z; Pei X; McCormick B; Powell SN; Ho A
Ann Surg Oncol; 2015 Aug; 22(8):2517-25. PubMed ID: 25564167
[TBL] [Abstract][Full Text] [Related]
10. Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy.
Huang Z; Zhu L; Huang XB; Tang Y; Rong QL; Shi M; Wang WH; Tie J; Shen LF; Chen JY; Zhang J; Wu HF; Cheng J; Liu M; Tan YT; Ma CY; Wang SL; Li YX
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1030-1039. PubMed ID: 32585337
[TBL] [Abstract][Full Text] [Related]
11. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.
Tendulkar RD; Rehman S; Shukla ME; Reddy CA; Moore H; Budd GT; Dietz J; Crowe JP; Macklis R
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e577-81. PubMed ID: 22560546
[TBL] [Abstract][Full Text] [Related]
12. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
14. Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry.
Miyashita M; Niikura N; Kumamaru H; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Tsuda H; Nakamura S; Tokuda Y
Ann Surg Oncol; 2019 Aug; 26(8):2475-2485. PubMed ID: 31102090
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).
Houvenaeghel G; Lambaudie E; Cohen M; Classe JM; Reyal F; Garbay JR; Giard S; Chopin N; Martinez A; Rouzier R; Daraï E; Colombo PE; Coutant C; Gimbergues P; Azuar P; Villet R; Tunon de Lara C; Barranger E; Sabiani L; Goncalves A
Breast; 2017 Aug; 34():24-33. PubMed ID: 28475932
[TBL] [Abstract][Full Text] [Related]
16. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
17. Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1-T2 breast cancer and 1-3 positive lymph nodes.
Moo TA; McMillan R; Lee M; Stempel M; Ho A; Patil S; El-Tamer M
Ann Surg Oncol; 2014 May; 21(5):1569-74. PubMed ID: 24488216
[TBL] [Abstract][Full Text] [Related]
18. Locoregional outcomes in clinical stage IIB breast cancer after neoadjuvant therapy and mastectomy with or without radiation.
Diaz DA; Hurley J; Reis I; Takita C; Zhao W; Wright J
Medicine (Baltimore); 2014 Dec; 93(29):e230. PubMed ID: 25546661
[TBL] [Abstract][Full Text] [Related]
19. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes.
Moo TA; McMillan R; Lee M; Stempel M; Patil S; Ho A; El-Tamer M
Ann Surg Oncol; 2013 Oct; 20(10):3169-74. PubMed ID: 23975289
[TBL] [Abstract][Full Text] [Related]
20. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
Tseng YD; Uno H; Hughes ME; Niland JC; Wong YN; Theriault R; Blitzblau RC; Moy B; Breslin T; Edge SB; Hassett MJ; Punglia RS
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):622-30. PubMed ID: 26461004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
